ArticleArchives of clinical toxicology2024
Non-alcoholic fatty liver disease: Role of PNPLA3 and its association with environmental chemicals.
Article in Archives of clinical toxicology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Globally, non-alcoholic fatty liver disease (NAFLD) is on the rise with 30-32%, 27-33%, 35-48%, 36%, 9-20%, and 36-38% prevalence in Asia, Europe, North America, South America, Africa, and Australia, respectively. Approximately, 5-10% of NAFLD proceeds to hepatitis called non-alcoholic steatohepatitis (NASH). NASH often progresses to liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Precise mechanism(s) for the development of HCC is not fully understood in NAFLD and NASH patients. Higher insulin levels in type 2 diabetes (T2D) can result in lipolysis of adipose tissue activating lipid synthesizing enzymes such as fatty acid synthase and stearoyl-CoA desaturase-1, resulting in lipid accumulation in liver. Higher levels of glucose in T2D patients activate carbohydrate response element binding protein and insulin which increases the level of active sterol regulatory element binding protein. These lipogenic transcription factors activate patatin-like phospholipase domain-containing protein-3 (PNPLA3) from their response elements in the promoter. Endocrine disrupting chemicals (EDCs) and persistent organic pollutants (POPs) are implicated in T2D development and NAFLD. The emerging association between POPs, including insecticides, fungicides, herbicides, and diabetes has been noted. However, their connection with NAFLD remains less evident. Here, we reviewed association of POPs, especially EDCs, and role of PNPLA3 in the development of NAFLD and NASH. We also reviewed the role of single nucleotide polymorphisms of PNPLA3's association with NAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.